Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
Background & Aims Long-term treatment with nucleos(t)ide analogues (NUCs) is associated with increasing rates of antiviral drug resistance. Medication adherence is important in preventing drug resistance. This study aimed to determine, first, the persistence rates and the adherence rates to NUCs...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2011-01, Vol.54 (1), p.12-18 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 18 |
|---|---|
| container_issue | 1 |
| container_start_page | 12 |
| container_title | Journal of hepatology |
| container_volume | 54 |
| creator | Chotiyaputta, Watcharasak Peterson, Carolyn Ditah, Fausta A Goodwin, Diane Lok, Anna S.F |
| description | Background & Aims Long-term treatment with nucleos(t)ide analogues (NUCs) is associated with increasing rates of antiviral drug resistance. Medication adherence is important in preventing drug resistance. This study aimed to determine, first, the persistence rates and the adherence rates to NUCs in patients with chronic hepatitis B (CHB), and second, the factors associated with adherence. Methods Pharmacy claims of three cohorts of patients with CHB who were receiving lamivudine, adefovir, or entecavir in January 2007, January 2008, and January 2009, and data of patients receiving tenofovir in January 2009, were analyzed. Persistence was defined as continuing acquisition of pharmacy claims during a 12-month period and adherence as the percent of days in which patients had medication during the period in which the medication was prescribed. Results A total of 11,100 patients were included, 4.7% were patients newly started on a NUC and 95.3% were existing patients already on a NUC at the start of each year. The mean ± SD persistence rate was 81 ± 3.8%, and was higher among existing patients than among new patients, 81.4% vs. 73.4% ( p 90%. Conclusions Persistence and adherence to NUCs were high among CHB patients. Counseling of young and/or new patients on medication adherence may decrease the rate of antiviral drug resistance. |
| doi_str_mv | 10.1016/j.jhep.2010.06.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_815551228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168827810007063</els_id><sourcerecordid>815551228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-de7fba227d3ac90e25dae2ba4cd14096cb58039a8780921a5341670b8ed5d2463</originalsourceid><addsrcrecordid>eNp9kV-L1DAUxYMo7uzqF_BB-iKuDx1v0jZNQQRd_AcLCrrPIU1undROM-amwn57U2dU8MGnkHPPuVx-h7FHHLYcuHw-bscdHrYCsgBym6U7bMMlQAmy5nfZJiuqVKJVZ-ycaASACrr6PjsToJSSkm_YzSeM5CnhbLEwsyuM22H89UuhmBc7YaDL9My7dWym8HXJk4gm7XFOxRBiYXcxzN4W-RaTfPJUvH7A7g1mInx4ei_Yzds3X67el9cf3324enVd2rqGVDpsh94I0brK2A5QNM6g6E1tHa-hk7ZvFFSdUa2CTnDTVDWXLfQKXeNELasL9vS49xDD9wUp6b0ni9NkZgwLacWbpuFCqOwUR6eNgSjioA_R70281Rz0SlOPeqWpV5oapM5SDj0-rV_6Pbo_kd_4suHJyWDImmmIZrae_voq2Yiuhex7cfRhhvHDY9Rk_QrZ-Yg2aRf8_-94-U_cTj4jN9M3vEUawxJzNaS5JqFBf157X2vnufEWZFX9BBkyp4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>815551228</pqid></control><display><type>article</type><title>Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Chotiyaputta, Watcharasak ; Peterson, Carolyn ; Ditah, Fausta A ; Goodwin, Diane ; Lok, Anna S.F</creator><creatorcontrib>Chotiyaputta, Watcharasak ; Peterson, Carolyn ; Ditah, Fausta A ; Goodwin, Diane ; Lok, Anna S.F</creatorcontrib><description>Background & Aims Long-term treatment with nucleos(t)ide analogues (NUCs) is associated with increasing rates of antiviral drug resistance. Medication adherence is important in preventing drug resistance. This study aimed to determine, first, the persistence rates and the adherence rates to NUCs in patients with chronic hepatitis B (CHB), and second, the factors associated with adherence. Methods Pharmacy claims of three cohorts of patients with CHB who were receiving lamivudine, adefovir, or entecavir in January 2007, January 2008, and January 2009, and data of patients receiving tenofovir in January 2009, were analyzed. Persistence was defined as continuing acquisition of pharmacy claims during a 12-month period and adherence as the percent of days in which patients had medication during the period in which the medication was prescribed. Results A total of 11,100 patients were included, 4.7% were patients newly started on a NUC and 95.3% were existing patients already on a NUC at the start of each year. The mean ± SD persistence rate was 81 ± 3.8%, and was higher among existing patients than among new patients, 81.4% vs. 73.4% ( p <0.001). The mean ± SD adherence rate was 87.8 ± 19.1% and was higher among existing patients than among new patients, 88% vs. 84.6% ( p = 0.001). Multivariate analysis showed that new patients (OR = 0.68, 95% CI 0.53–0.86), those receiving lamivudine (OR = 0.66, 95% CI 0.58–0.76), and young adult patients (OR = 0.82, 95% CI 0.74–0.91) were less likely to have adherence rate >90%. Conclusions Persistence and adherence to NUCs were high among CHB patients. Counseling of young and/or new patients on medication adherence may decrease the rate of antiviral drug resistance.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2010.06.016</identifier><identifier>PMID: 20888661</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adefovir dipivoxil ; Adenine - analogs & derivatives ; Adenine - therapeutic use ; Adolescent ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; Antiviral resistance ; Biological and medical sciences ; Cohort Studies ; Compliance ; Drug Resistance, Viral ; Entecavir ; Female ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - psychology ; Human viral diseases ; Humans ; Infectious diseases ; Lamivudine ; Lamivudine - therapeutic use ; Male ; Medical sciences ; Medication Adherence - statistics & numerical data ; Middle Aged ; Organophosphonates - therapeutic use ; Pharmacology. Drug treatments ; Retrospective Studies ; Tenofovir ; Tenofovir disoproxil fumarate ; Viral diseases ; Viral hepatitis ; Young Adult</subject><ispartof>Journal of hepatology, 2011-01, Vol.54 (1), p.12-18</ispartof><rights>European Association for the Study of the Liver</rights><rights>2010 European Association for the Study of the Liver</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-de7fba227d3ac90e25dae2ba4cd14096cb58039a8780921a5341670b8ed5d2463</citedby><cites>FETCH-LOGICAL-c440t-de7fba227d3ac90e25dae2ba4cd14096cb58039a8780921a5341670b8ed5d2463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827810007063$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23652970$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20888661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chotiyaputta, Watcharasak</creatorcontrib><creatorcontrib>Peterson, Carolyn</creatorcontrib><creatorcontrib>Ditah, Fausta A</creatorcontrib><creatorcontrib>Goodwin, Diane</creatorcontrib><creatorcontrib>Lok, Anna S.F</creatorcontrib><title>Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background & Aims Long-term treatment with nucleos(t)ide analogues (NUCs) is associated with increasing rates of antiviral drug resistance. Medication adherence is important in preventing drug resistance. This study aimed to determine, first, the persistence rates and the adherence rates to NUCs in patients with chronic hepatitis B (CHB), and second, the factors associated with adherence. Methods Pharmacy claims of three cohorts of patients with CHB who were receiving lamivudine, adefovir, or entecavir in January 2007, January 2008, and January 2009, and data of patients receiving tenofovir in January 2009, were analyzed. Persistence was defined as continuing acquisition of pharmacy claims during a 12-month period and adherence as the percent of days in which patients had medication during the period in which the medication was prescribed. Results A total of 11,100 patients were included, 4.7% were patients newly started on a NUC and 95.3% were existing patients already on a NUC at the start of each year. The mean ± SD persistence rate was 81 ± 3.8%, and was higher among existing patients than among new patients, 81.4% vs. 73.4% ( p <0.001). The mean ± SD adherence rate was 87.8 ± 19.1% and was higher among existing patients than among new patients, 88% vs. 84.6% ( p = 0.001). Multivariate analysis showed that new patients (OR = 0.68, 95% CI 0.53–0.86), those receiving lamivudine (OR = 0.66, 95% CI 0.58–0.76), and young adult patients (OR = 0.82, 95% CI 0.74–0.91) were less likely to have adherence rate >90%. Conclusions Persistence and adherence to NUCs were high among CHB patients. Counseling of young and/or new patients on medication adherence may decrease the rate of antiviral drug resistance.</description><subject>Adefovir dipivoxil</subject><subject>Adenine - analogs & derivatives</subject><subject>Adenine - therapeutic use</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral resistance</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Compliance</subject><subject>Drug Resistance, Viral</subject><subject>Entecavir</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - psychology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Lamivudine</subject><subject>Lamivudine - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication Adherence - statistics & numerical data</subject><subject>Middle Aged</subject><subject>Organophosphonates - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Tenofovir</subject><subject>Tenofovir disoproxil fumarate</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Young Adult</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV-L1DAUxYMo7uzqF_BB-iKuDx1v0jZNQQRd_AcLCrrPIU1undROM-amwn57U2dU8MGnkHPPuVx-h7FHHLYcuHw-bscdHrYCsgBym6U7bMMlQAmy5nfZJiuqVKJVZ-ycaASACrr6PjsToJSSkm_YzSeM5CnhbLEwsyuM22H89UuhmBc7YaDL9My7dWym8HXJk4gm7XFOxRBiYXcxzN4W-RaTfPJUvH7A7g1mInx4ei_Yzds3X67el9cf3324enVd2rqGVDpsh94I0brK2A5QNM6g6E1tHa-hk7ZvFFSdUa2CTnDTVDWXLfQKXeNELasL9vS49xDD9wUp6b0ni9NkZgwLacWbpuFCqOwUR6eNgSjioA_R70281Rz0SlOPeqWpV5oapM5SDj0-rV_6Pbo_kd_4suHJyWDImmmIZrae_voq2Yiuhex7cfRhhvHDY9Rk_QrZ-Yg2aRf8_-94-U_cTj4jN9M3vEUawxJzNaS5JqFBf157X2vnufEWZFX9BBkyp4g</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Chotiyaputta, Watcharasak</creator><creator>Peterson, Carolyn</creator><creator>Ditah, Fausta A</creator><creator>Goodwin, Diane</creator><creator>Lok, Anna S.F</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B</title><author>Chotiyaputta, Watcharasak ; Peterson, Carolyn ; Ditah, Fausta A ; Goodwin, Diane ; Lok, Anna S.F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-de7fba227d3ac90e25dae2ba4cd14096cb58039a8780921a5341670b8ed5d2463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adefovir dipivoxil</topic><topic>Adenine - analogs & derivatives</topic><topic>Adenine - therapeutic use</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral resistance</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Compliance</topic><topic>Drug Resistance, Viral</topic><topic>Entecavir</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - psychology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Lamivudine</topic><topic>Lamivudine - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication Adherence - statistics & numerical data</topic><topic>Middle Aged</topic><topic>Organophosphonates - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Tenofovir</topic><topic>Tenofovir disoproxil fumarate</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chotiyaputta, Watcharasak</creatorcontrib><creatorcontrib>Peterson, Carolyn</creatorcontrib><creatorcontrib>Ditah, Fausta A</creatorcontrib><creatorcontrib>Goodwin, Diane</creatorcontrib><creatorcontrib>Lok, Anna S.F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chotiyaputta, Watcharasak</au><au>Peterson, Carolyn</au><au>Ditah, Fausta A</au><au>Goodwin, Diane</au><au>Lok, Anna S.F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>54</volume><issue>1</issue><spage>12</spage><epage>18</epage><pages>12-18</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background & Aims Long-term treatment with nucleos(t)ide analogues (NUCs) is associated with increasing rates of antiviral drug resistance. Medication adherence is important in preventing drug resistance. This study aimed to determine, first, the persistence rates and the adherence rates to NUCs in patients with chronic hepatitis B (CHB), and second, the factors associated with adherence. Methods Pharmacy claims of three cohorts of patients with CHB who were receiving lamivudine, adefovir, or entecavir in January 2007, January 2008, and January 2009, and data of patients receiving tenofovir in January 2009, were analyzed. Persistence was defined as continuing acquisition of pharmacy claims during a 12-month period and adherence as the percent of days in which patients had medication during the period in which the medication was prescribed. Results A total of 11,100 patients were included, 4.7% were patients newly started on a NUC and 95.3% were existing patients already on a NUC at the start of each year. The mean ± SD persistence rate was 81 ± 3.8%, and was higher among existing patients than among new patients, 81.4% vs. 73.4% ( p <0.001). The mean ± SD adherence rate was 87.8 ± 19.1% and was higher among existing patients than among new patients, 88% vs. 84.6% ( p = 0.001). Multivariate analysis showed that new patients (OR = 0.68, 95% CI 0.53–0.86), those receiving lamivudine (OR = 0.66, 95% CI 0.58–0.76), and young adult patients (OR = 0.82, 95% CI 0.74–0.91) were less likely to have adherence rate >90%. Conclusions Persistence and adherence to NUCs were high among CHB patients. Counseling of young and/or new patients on medication adherence may decrease the rate of antiviral drug resistance.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20888661</pmid><doi>10.1016/j.jhep.2010.06.016</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2011-01, Vol.54 (1), p.12-18 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_815551228 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adefovir dipivoxil Adenine - analogs & derivatives Adenine - therapeutic use Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Antiviral resistance Biological and medical sciences Cohort Studies Compliance Drug Resistance, Viral Entecavir Female Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - psychology Human viral diseases Humans Infectious diseases Lamivudine Lamivudine - therapeutic use Male Medical sciences Medication Adherence - statistics & numerical data Middle Aged Organophosphonates - therapeutic use Pharmacology. Drug treatments Retrospective Studies Tenofovir Tenofovir disoproxil fumarate Viral diseases Viral hepatitis Young Adult |
| title | Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T13%3A44%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistence%20and%20adherence%20to%20nucleos(t)ide%20analogue%20treatment%20for%20chronic%20hepatitis%20B&rft.jtitle=Journal%20of%20hepatology&rft.au=Chotiyaputta,%20Watcharasak&rft.date=2011-01-01&rft.volume=54&rft.issue=1&rft.spage=12&rft.epage=18&rft.pages=12-18&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2010.06.016&rft_dat=%3Cproquest_cross%3E815551228%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=815551228&rft_id=info:pmid/20888661&rft_els_id=1_s2_0_S0168827810007063&rfr_iscdi=true |